Detalhe da pesquisa
1.
The impact of Demodex blepharitis on patient symptoms and daily life.
Optom Vis Sci
; 101(3): 151-156, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546756
2.
Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).
Ophthalmology
; 130(10): 1015-1023, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285925
3.
Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.
Ophthalmology
; 129(4): 379-387, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34767866
4.
In Vitro Antibiotic Resistance among Bacteria from the Cornea in the Antibiotic Resistance Monitoring in Ocular MicRoorganisms Surveillance Study.
Optom Vis Sci
; 98(9): 1113-1121, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34510155
5.
Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE.
Cornea
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38771801
6.
Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
J Ocul Pharmacol Ther
; 39(9): 600-610, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37677000
7.
Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions.
Clin Ophthalmol
; 16: 3803-3809, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36419563